There are only 14 days left until the 58th Annual Meeting & Exposition of the American Society of Hematology (ASH).
For over 50 years, the ASH annual meeting has been considered the premier event for the exchange of scientific knowledge, specifically in the field of malignant and non-malignant hematology. This event is typically attended by more than 20,000 hematology professionals, from every speciality, from across the globe making it the perfect opportunity to network with the top minds in the field. Each year, ASH receive over 5,000 abstracts for this event, of which over 3,000 pass the extensive peer review process and are accepted for poster and oral presentations. The highlight of the event is considered to be the Plenary Scientific Session, where the top 6 abstracts, selected by the Program Committee, are presented and discussed.
The AML Global Portal (AGP) had a fantastic few days reporting live from ASH 2015, held in Orlando. We live reported and tweeted each day on a number of exciting sessions which focused on a range of different topics including:
- Advances in therapy
- Advances in targeted therapy
- New approaches using older drugs
- Novel therapy (excluding transplantation)
Other interesting presentations included clinical and molecular characterization of p53-mutated AML, a Satellite Symposia on novel and emerging therapeutics, and numerous presentations on SGN-CD33A demonstrating anti-leukemic activity in Acute Myeloid Leukemia (AML).
In addition, at last year’s event, the AGP interviewed top experts in the field of malignant hematology; we discussed results of the CALGB 10603/RATIFY study with Dr Richard Stone, we interviewed Prof. Rüdiger Hehlmann on activities of the European LeukemiaNet (ELN) and future challenges the ELN faces, and we asked Dr Paul Ferguson what is his definition of Primary Refractory AML.
This year’s ASH Annual Meeting & Exposition is taking place at the San Diego Convention Center, California, from 3–6 December, and the AGP will be there. Be sure to visit The AML Global Portal for coverage of oral abstracts, educational sessions, and interviews with speakers and our Steering Committee members.